Nosantine racemate (NPT-15392 racemate) |
| Catalog No.GC33873 |
Nosantine racemate (NPT-15392 racemate) is the racemate of Nosantine.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 75166-67-5
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Nosantine racemate is the racemate of Nosantine. Nosantine is an inducer of IL-2 or enhancer of IL-2 induction by phytohemagglutinin (PHA).
The purine immunoenhancing drug Nosantine (NPT 15392) is evaluated as an inducer of IL-2 or enhancer of IL-2 induction by phytohemagglutinin (PHA). Nosantine is found to has significant enhancing activity on PHA induction of IL-2 by human lymphocytes over a wide range of concentrations[1].
Multiple concomitant immune responses are assessed in individual rats following treatment with the immunoenhancing drugs, Isoprinosine (5 or 50 mg/kg), Nosantine (0.1 or 1.0 mg/kg) and Avridine (1 or 25 mg/kg), or the immunosuppressant, Cyclophosphamide (75 mg/kg). Rats treated with Nosantine (NPT 15392) have significantly enhanced DTH reactions at the 0.1 mg/kg dose. It can be concluded that NPT 15392 act as general immunostimulants in the rat, with avridine having the greatest effect under these experimental conditions[2].
[1]. Wiranowska-Stewart M, et al. Effects of isoprinosine and NPT 15392 on interleukin-2 (IL-2) production. Int J Immunopharmacol. 1986;8(1):63-9. [2]. Exon JH, et al. The selectivity of isoprinosine, NPT 15392, avridine and cyclophosphamide on multiple immuneresponses in rats. Int J Immunopharmacol. 1986;8(1):53-62.
Animal experiment: | Rats[2] Animals in seven of the groups are also injected subcutaneously with various dosage regimens of the immunomodulating drugs, isoprinosine (ISO), Nosantine (NPT 15392), avridine (AVD) and cyclophosphamide (CY). Individual rats in each group receive drug treatments consisting of 5 or 50 mg/kg ISO, 0.1 or 1.0 mg/kg Nosantine, 1 or 25 mg/kg AVD, or 75 mg/kg CY. Injections of ISO, Nosantine and AVD are given at three separate time intervals in relation to injection with bovine serum albumin (BSA). Isoprinosine and Nosantine are given twice at the same time as each BSA injection and a third time 3 days before termination. All rats are sacrificed by asphyxiation with CO2 and assayed for immunocompetence 14 days after the initial BSA and KLH injections. Six separate immunoassays are performed to assess different immune responses in the same animal. |
References: [1]. Wiranowska-Stewart M, et al. Effects of isoprinosine and NPT 15392 on interleukin-2 (IL-2) production. Int J Immunopharmacol. 1986;8(1):63-9. | |
| Cas No. | 75166-67-5 | SDF | |
| Canonical SMILES | O=C1N=CNC2=C1N=CN2C(C(O)C)CCCCCC | ||
| Formula | C14H22N4O2 | M.Wt | 278.35 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5926 mL | 17.963 mL | 35.926 mL |
| 5 mM | 0.7185 mL | 3.5926 mL | 7.1852 mL |
| 10 mM | 0.3593 mL | 1.7963 mL | 3.5926 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 11 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *